MethodSense announced the launch of its Capital & Investment Strategy advisory practice, designed to align regulatory intelligence with capital decisions across the MedTech lifecycle.
As the funding environment evolves, investors are scrutinizing regulatory timelines, milestone credibility, and execution discipline earlier and more rigorously than in prior cycles. Increasingly, regulatory realism determines whether companies secure funding, and whether investments perform as expected and access to capital.
The new advisory practice integrates regulatory expertise with capital alignment to support:
- Companies raising capital: validating regulatory roadmaps and aligning milestones to achievable inflection points, preparing outreach materials, and developing lists of qualified investors
- Investors and OEM partners: stress-testing regulatory assumptions before and after capital deployment
- Companies approaching approval or transaction events: advising on best practices to approach strategic or financial buyers based on your specific market strengths and execution discipline and transaction readiness
- Boards overseeing challenged assets: communicating with the FDA to reset FDA-aligned timelines and restoring capital confidence
Rather than functioning as investment bankers or placement agents, MethodSense provides independent regulatory intelligence to increase the probability that capital is deployed against credible and achievable milestones.
“In today’s MedTech environment, regulatory strategy doesn’t just determine clearance, it determines whether a company is viewed as fundable, scalable, and capable of delivering on its milestones. Our role is to ensure capital strategy reflects regulatory reality.”
Rita King, CEO and Regulatory Strategist at MethodSense
Richard Holcomb, Chief Growth Officer at MethodSense, will lead the initiative. Holcomb brings more than 40 years of experience in capital formation and M&A, including raising over $100 million in venture funding and participating in hundreds of millions of dollars in liquidity events.
More information is available at: methodsense.com/capital
